Abstract Invasive ductal carcinomas (IDC) of the breast with the triple negative phenotype (steroid hormone receptor absent, negative HER2 status) are characterized by poor clinical outcome. Additional tumor markers might allow identification of patients at higher risk. We evaluated clinical and biological features of 284 consecutive patients with pT1-3, pN1-3 M0 triple-negative IDC. Median follow-up was 70 months (interquartile range 59-94 months). Statistically significant worse disease-free and overall survival were observed in multivariate analysis, for patients with EGFR immunoreactivity in C50% invasive tumor cells (HR 2.39, 95% CI, 1.32-4.34, P = 0.004 for DFS; HR 2.34, 95% CI, 1.20-4.59 P = 0.01 for OS). Age C 70 years and PVI were additional independent predictors of reduced overall survival. EGFR immunoreactivity significantly correlates with worse prognosis in patients with triple-negative IDC, supporting further studies on the correlation between the degree of EGFR expression and outcome of triple negative breast cancer.
Introduction
Recent studies of gene expression profiling have led to the identification of breast cancer subtypes based on common molecular features [1, 2] . The basal like group is composed almost entirely of the so-called ''triple negative'' cancers, characterized by the lack of any estrogen (ER) and progesterone receptor (PgR) immunoreactivity and of HER2/ neu over-expression.
Positive markers of this group of tumors are basal-cell cytokeratins including cytokeratins (CK) 5/6, 14 and 17 [3] which are normally found in the basal layer of stratified epithelia [2, 3] . Whether identified by the expression of basal immunohistochemical markers [4, 5] or by a basal-like RNA expression profile [6] , these tumors represent about 15% of all breast cancers [7] and are characterized by an adverse clinical course, with an increased likelihood of disease recurrence and death [1, 8] . There is currently no specific targeted treatment for patients with triple-negative breast cancers, due to the lack of data on which to base treatment selection.
An easily obtainable immunohistochemical profile is the most suitable approach for the proper identification of triple-negative breast cancers, but immunohistochemical markers are of little prognostic value for these tumors, largely because they have been assessed in old retrospective series with small sample sizes and collected over several years. Furthermore, it should be emphasized that triplenegative breast cancers currently include a heterogeneous group of tumors, and that the identification of tumor subtypes amenable to targeted treatments still represents a research priority. Immunohistochemical studies documented a high rate of epithelial growth factor receptor (EGFR; also known as HER1) expression in triple-negative breast cancers [8, 9] . In a recently published study, 57% of basal-like cancers overexpressed EGFR, compared with 8% (P \ 0.001) of an independent series of cancers that were defined as non-basal-like by lack of CK 5/6 staining [9] .
The aim of this retrospective study was to evaluate the possible prognostic role of a selected number of morphological and immunohistochemical features, according to REMARK recommendations [10] . We focused on the prognostic role of EGFR immunoreactivity in a large series of triple-negative breast cancer patients, who had a homogeneous diagnostic and therapeutic environment.
Materials and methods

Patients
For the present study, those patients with invasive ductal NOS breast cancer without any expression of ER and PgR and with no overexpression of HER2/neu were considered as eligible. Patients with invasive adenoid cystic, apocrine and typical medullary tumors were excluded from the analysis considering their peculiar clinicopathological features and favorable outcome [11] [12] [13] . Patients who presented with recurrent tumor, metastatic disease at presentation, non-invasive breast cancers, other previous tumor, bilateral tumors, or who had previously received neo-adjuvant treatment were also excluded.
All patients received adequate local treatment (breast conserving surgery or total mastectomy) with sentinel node (SLN) biopsy or complete axillary dissection. Patients with primary breast cancer were assigned to SLN biopsy in case of cytologically or histologically verified breast carcinoma 3 cm or less in size (measured clinically and/or by imaging techniques) and clinically uninvolved axillary lymph nodes. SLN biopsy was followed by axillary dissection only if the SLN contained metastasis or where there was minimal node involvement. The SLN was identified and isolated using a gamma probe as a guide, as previously published [14] . Postoperative breast irradiation (RT) was proposed to all patients who received breast-conserving surgery, excluding only those few elderly patients for whom radiation was considered inappropriate [15] . Systemic adjuvant therapy was recommended according to recent St. Gallen Consensus Conferences Guidelines [16, 17] . Six months of adjuvant chemotherapy were considered for patients with triple-negative IDC. In particular, the selection of adjuvant chemotherapy was based upon indicators of risk. For patients with node-negative disease, classical CMF (oral cyclophosphamide, methotrexate and fluorouracil) for a duration of 6 cycles was considered [18] . For patients at higher risk (e.g., with tumors exhibiting PVI, pN1a disease) anthracycline containing chemotherapy was considered as the first option (e.g., AC, adriamycin and cyclophoshamide), for 4 cycles followed by classical CMF for three courses [19] or intensive CEF [20] according to the degree of patient risk.
Specimen characteristics and assay methods
Pathological assessment included evaluation of the primary tumor size, grade and histological type, and of lymph node status following axillary lymph node dissection or a SLN biopsy [21] . Tumor grade was evaluated according to Elston and Ellis [22] and peritumoral vascular invasion (PVI) was assessed according to Rosen et al. [23] . Central necrosis and fibrosis were assessed according to Tsuda et al. [24] . Estrogen (ER) and progesterone receptor (PgR) status, Ki-67 labeling index determined with the MIB1 monoclonal antibody, and HER2/neu overexpression were evaluated immunocytochemically as previously reported [25] . For evaluation of ER and PgR status and Ki-67 labeling index, the percentage of cells exhibiting definite nuclear staining over at least 2,000 neoplastic cells examined at 4009 magnification was recorded. Only nuclear immunoreactivity was evaluated for ER, PgR, and MIB1. The threshold for the definition of triple-negative breast cancer was lack of any ER and PgR immunoreactivity and a 0-2? scoring for HER2/neu as previously published [25] .
Immunostaining for p63, CK 5/6, CK 14 and EGFR was performed using the following monoclonal antibodies: D5/16 B4 for CK5/6 (used at 1:100 dilution; Dako, Glostrup, Denmark); LL002 for CK 14 (at 1:80 dilution, NovoCastra, Newcastle Upon Tyne, UK); 4A4 for p63 (at 1:100 dilution, Dako) 31G7 for EGFR (at 1:20 dilution, Zymed Laboratories). Only cytoplasmic immunoreactivity was evaluated for CK 5/6 and 14, membrane and cytoplasmic for EGFR, and only nuclear immunoreactivity for p63. Immunohistochemical results for EGFR were recorded as the percentage of invasive tumor cells showing definite immunoreactivity for the corresponding antigen over at least 2,000 neoplastic cells examined at 4009 magnification.
In accordance with Banerjee et al. [26] , no threshold for cytokeratin positivity was used. Any definite immunoreactivity in neoplastic cells was classified as positive. Similarly, any nuclear staining for p63 was considered positive in accordance with Ribeiro-Silva et al. [27] .
Data were entered by surgeons into a 'user-friendly' Microsoft Access Ò database once weekly for a mean number of 25 patients per week, and checked by a data manager. The database was then used for an interdisciplinary discussion (among surgeons, medical and radiation oncologists and pathologists) resulting in the proposal for an adjuvant treatment program. Typically, a medical oncologist (and a radiation oncologist, where applicable) discussed the proposed treatment with the patient and verified the accuracy of the items entered into the database (internal quality control). The primary endpoints were disease-free survival (DFS) and overall survival (OS). DFS was defined as the length of time from the date of surgery to any relapse (including ipsilateral breast recurrence), the appearance of a second primary cancer (including contralateral breast cancer), or death, whichever occurred first. OS was determined as the time from surgery until the date of death (from any cause) or the date of last follow-up. Secondary end points were distant metastasis free survival (DDFS), breast-related event-free survival (BREFS). BREFS was defined as the time from the date of surgery to any breast-related event.
Statistical analysis methods
The Mantel-Haenszel Chi-Square test for trend was used to assess the association between ordinal variables. Multivariate Cox proportional hazard regression analysis was used to assess the independent prognostic significance of various clinical and histopathological characteristics of the tumor on survival. Factors included in multiple regression analyses included age, pathological stage, degree of nodal involvement, PVI and EGFR expression set either as a categorical variable with three levels of expression (negative, 1-49, C50) or as a continuous variable with the hazard ratios given for a 10% increase of the expression.
All analyses were performed with the SAS software (Cary, NC). All tests were two-sided.
Results
Overall, 6,242 consecutive patients were referred for interdisciplinary evaluation between April 1997 and December 2001 and 4,993 had invasive, monolateral, nonmetastatic, and untreated breast cancer.
For 2,177 of these patients HER2/neu was not determined, a further 2,481 patients had either endocrine responsive tumors and/or tumors overexpressing HER2/ neu; 51 of the remaining patients had non ductal NOS tumors. Therefore, 284 patients with triple-negative IDC were eligible for the present analysis and their characteristics are shown in Table 1 .
A total of 245 patients (86%) had tumors with a ''basallike'' phenotype, based on immunoreactivity for p63, basal CKs and/or for EGFR. In particular, p63 immunoreactivity was documented in the tumors of 136 patients, CK14 in 153 cases, CK5/6 in 90 and EGFR in 163 cases, with 36 of the latter tumors exhibiting immunoreactivity in C50% neoplastic cells. Tumors with the triple-negative phenotype were commonly of high grade (85% of patients) and had large size ([2 cm, 54% of patients); 166 patients were classified pN0 whereas 115 patients had one to three metastatic axillary lymph nodes.
Treatments performed are shown in Table 2 . Forty-eight patients had a total mastectomy as the primary treatment, 236 patients underwent breast conserving surgery and 86 had SLN biopsy. Radiotherapy was performed in 238 patients. The majority of the patients (263, 93%) were submitted to adjuvant chemotherapy. About half of them (138, 52%) were submitted to classical CMF (oral cyclophosphamide, methotrexate and fluorouracil) for a duration of six courses. Elderly patients compared with younger patients, were less likely to receive adjuvant chemotherapy as well as patients without PVI (P \ 0.0001). No significant difference in the prescription of chemotherapy was observed according to EGFR expression (Table 2 ).
Analysis and presentation
Median follow-up was 70 months (interquartile range: 59-94 months). Types of events according to patient characteristics, and the event rates (defined as the incidence rate per 1,000 women/year) are shown in Table 3a .
We selected a cutoff of 50% membranous/cytoplasmic expression which corresponded to the 90th percentile of the distribution of EGFR in our series. The prognostic value of EGFR using other cutoff values (10 and 30%; Fig. 1 ) was evaluated and the prognostic value of EGFR as a continuous variable was also assessed (Table 4) . Four-year DFS for patients whose tumors showed EGFR immunoreactivity in \50 or C50% of the neoplastic cells was 79 versus 52% (log-rank P \ 0.0001), and 4 years OS was 87 versus 81%, respectively, (log-rank P = 0.0004). Also, 4 year BREFS and DDFS were 81 versus 58%, (logrank P = 0.0002) and 90 versus 68% (log-rank P \ 0.0001) respectively.
Among the other clinico-pathological features investigated, tumor size, lymph node status, PVI, immunoreactivity for CK5/6 were correlated with DFS and/or OS (Table 3a) . Table 3b reports the results of the univariate analysis of event rates according to the type of treatments. Only the extent of surgery was significantly correlated with the risk of BREFS, DFS and OS, while no correlation with the chemotherapy regimen was observed.
Multivariate analysis
We investigated the independent association between biological features and risk of relapse using the Cox proportional hazards regression analysis (Table 4) . A statistically significant worse outcome was observed in multivariate analysis for patients with tumors exhibiting EGFR expression in C50% of the neoplastic cells versus the patients with tumors lacking any EGFR expression (HR 2.39, 95% CI, 1.32-4.34, P = 0.004 for DFS; HR 2.34, 95% CI, 1.20-4.59 P = 0.01 for OS; HR 3.39, 95% CI, 1.52-7.60, P = 0.003 for DDFS and HR 2.27, 95% CI, Bold is statistically significant 
Discussion
Emerging data on the clinical implications of IDC with the triple-negative phenotype indicates an aggressive course of the disease. Despite the widespread acknowledgment of the poor clinical outcome, the prognostic value of specific morphological and biological features of these tumors continues to raise a substantial degree of uncertainty and controversy [5, 8, 28] . Data from past series include information on several characteristics of the disease collected in the earlier period, when neither systemic treatments nor various prognostic and predictive factors were available as they are today. Adjuvant systemic therapies and precise assessment of the biological features of primary breast cancers are probably the most relevant innovations in the current treatment of breast carcinoma patients. Recent therapeutic strategies emphasize the paramount importance of targeted therapies wherever possible, though acknowledging that supplementation with less target-specific chemotherapy may be required [29] . This study provides useful insights into the treatment and prognosis of breast cancer since it is based on a large number of patients, collected in a relatively short time, thus allowing the adoption of modern procedures. The pathologists, surgeons and medical oncologists used consistent approaches during the years of reference. Adjuvant treatment proposed was largely based on the degree of nodal involvement as well as on known prognostic features according to recent St. Gallen Consensus Conferences Guidelines [16, 17] .
From the current study, the extent of EGFR immunoreactivity in triple-negative IDC of the breast emerges as a clinically relevant prognostic parameter. Recently reported studies already indicated that EGFR expression is associated with significant worse DFS in early breast cancer [30] . A comparison between triple negative tumors (defined as ER, PgR and HER2 negative) and the so-called ''five marker'' tumors, defined also by the presence of EGFR and Fig. 1 Kaplan Meier curves of disease free survival (DFS), distant metastasis free survival (DDFS) and overall survival (OS) according to different cut off levels of EGFR expression CK 5 and 6, showed a poorer prognosis for the latter group, underscoring the relevance of EGFR expression among basal-like tumors [31] . However, the actual value of the quantitative evaluation of EGFR immunoreactivity is still uncertain.
The present study confirms previous published results indicating a different outcome for patients with triple negative IDC, according to the extent of EGFR immunoreactivity (defined as percentage of positive cells). Indeed, patients whose tumors lack EGFR immunoreactivity or show low levels of expression have similar outcomes as opposed to patients with tumors characterized by more extensive EGFR immunoreactivity (i.e., C50% of the neoplastic cells) who exhibit poorer DFS (HR 2.39; P = 0.004) and OS (HR 2.34; P = 0.01). A theoretical implication of these results may be the exploration of selective HER1 inhibitors in the adjuvant treatment of IDC of the breast with the ''triple-negative'' phenotype and extensive immunoreactivity for EGFR. Limited activity was recently shown in a small group of patients, unselected for EGFR expression, and treated with an EGFR tyrosine kinase inhibitor [32] . The results of the present study support further investigations to exploit the role of these agents in patients whose tumors express EGFR.
Setting thresholds in a biological continuum as the extent of EGFR immunoreactivity may well be considered arbitrary, but despite this it may prove clinically useful to identify patients at higher risk who may benefit from targeted treatments. The percentage of neoplastic cells exhibiting peculiar biological features is already considered relevant in the assessment of prognostic and predictive factors in early breast cancer. A similar arbitrary cut-off of [30% immunoreactive tumor cells has recently been proposed for the assessment of HER2/neu-positive breast cancers [33] . Also the percentage of neoplastic cells immunoreactive for hormone receptors is currently considered of paramount value in assessing tumor endocrine responsiveness and in planning targeted treatments [29, 34] .
In the present study we evaluated the prognostic value of EGFR either as a continuous variable and through different cut-off values (10, 30 and 50%). We selected a cut-off of 50% (which corresponded to the 90th percentile in our series) bearing in mind that this cut-off has been used in other series of solid tumors [35] . It has been shown that the EGFR gene copy number was associated with a worse prognosis in non small cell lung cancer (NSCLC) [36] . Moreover, a correlation between EGFR immunoreactivity and EGFR gene copy number has been demonstrated in NSCLC [37] . Considering that EGFR immunohistochemistry is a widely applicable and inexpensive test, in contrast to the evaluation of EGFR copy number and mutations, the assessment of the percentage of immunohistochemically positive cells might be a useful approach to defining the degree of EGFR expression.
Similarly, HER-2 gene copy number has been closely associated with HER-2 protein expression, both predicting worse prognosis [29] . In a previous study we showed that the extent of HER2 protein expression was significantly correlated with HER2 gene amplification. In fact, only 21.4% of the tumors with positive immunostaining in B50% of cells showed gene amplification which compares with 85.7% of the tumors presenting a positive staining in [50% of cells [38] . These results support the hypothesis that an higher expression of positivity through IHC (e.g., [50% of the cells) might identify subgroups of tumors with gene amplification.
The results of the present study show that age C70 years is an important prognostic factor, associated with a threefold increased risk of relapse, metastases and breast related events when compared with younger patients. However, these results were observed in a population subjected to an adjuvant therapy program which might have interfered with the outcome. As shown in Table 2 , elderly patients received significantly less chemotherapy and in particular anthracycline-containing chemotherapy than younger patients. In fact, according to the limited data available in the literature on the value of adjuvant chemotherapy in elderly patients [20, 39] , women aged C70 yrs were typically not submitted to an adjuvant chemotherapy program. The poor prognosis observed in the present analysis for this subgroup of patients, supports appropriate discussions with patients on the costs and benefits of adjuvant chemotherapy.
In the multivariate analysis other known prognostic factors, such as pathological stage, were found to be significantly associated with the outcome of the patients. As shown in Table 4 , the occurrence of PVI was an independent predictor of overall mortality (HR 1.98) and was associated with worse DFS, DDFS and BREFS although these last associations were of borderline statistical significance. Although these data are in line with recently published data and support a prognostic role for PVI in early breast cancer [40] , limited information is available on the role of PVI in the cohort of patients with triple-negative IDC. All these factors should be properly taken into account in the treatment decision-making procedure.
It has been previously demonstrated that expression of basal cytokeratins (CK 5/6 and/or CK 14/17) predicts poor outcome [8, 9] in breast carcinoma patients, and in particular in the node-positive group of patients [41] . The prognostic role of basal cytokeratins might be related to the identification of the subgroup of patients with basal-like phenotype. Limited and controversial data, however, are available on the prognostic value of basal cytokeratins in the cohort of patients with triple-negative IDC. Jumppanen et al. found that within the subgroup of ER-negative tumors, the clinical outcome of tumors characterized by the expression of basal e cytokeratins (CK5/14/17) was similar to that of ER-negative tumors lacking any immunoreactivity for these markers [42] .
Large central necrosis or fibrosis have also been reported to correlate with poor prognosis in early breast cancer [43] , and to be strongly associated with basal-like [44] and ER-negative breast cancer [45] . Information on their prognostic value within the subgroup of triple-negative IDC is, however, lacking. In the current study immunoreactivity for basal cytokeratins and occurrence of central necrosis were not independent predictors of survival. A significant proportion of the patients with triplenegative IDC might have tumors concomitantly showing intratumoral necrosis [28] , a EGFR and basal cytokeratins immunoreactivity [46] . This may explain why these closely associated factors are not all independently predicting DFS or OS when taken together in the full regression models.
The efficacy of adjuvant systemic therapy for early breast cancer depends on several variables, which include features of the tumor, the patient and the treatment itself. In the present study, conducted in a single institution, we demonstrated that the extent of EGFR immunoreactivity significantly correlates with prognosis in triple-negative IDC. Despite the statistically significant detrimental prognostic effect associated with EGFR expression, the potential for bias still exists due to the retrospective nature of the evaluation and the arbitrary cut-off selection. Further studies using database analyses or prospective trials are required to confirm the prognostic value of the extent of EGFR expression. If the results of the present study are confirmed, EGFR expression should be included in the routine immunohistochemical assessment of triple negative breast cancer.
